Coherus BioSciences Inc - Asset Resilience Ratio
Coherus BioSciences Inc (CHRS) has an Asset Resilience Ratio of 32.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CHRS strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Coherus BioSciences Inc's Asset Resilience Ratio has changed over time. See Coherus BioSciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Coherus BioSciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Coherus BioSciences Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $83.25 Million | 32.22% |
| Total Liquid Assets | $83.25 Million | 32.22% |
Asset Resilience Insights
- Very High Liquidity: Coherus BioSciences Inc maintains exceptional liquid asset reserves at 32.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Coherus BioSciences Inc Industry Peers by Asset Resilience Ratio
Compare Coherus BioSciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Coherus BioSciences Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Coherus BioSciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.22% | $83.25 Million | $258.34 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $448.53 Million | -- |
| 2023-12-31 | 2.36% | $14.86 Million | $629.60 Million | -24.29pp |
| 2022-12-31 | 26.65% | $128.13 Million | $480.85 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $679.33 Million | -- |
| 2017-12-31 | 0.04% | $60.00K | $162.61 Million | +0.00pp |
| 2016-12-31 | 0.03% | $60.00K | $178.49 Million | +0.01pp |
| 2015-12-31 | 0.03% | $60.00K | $212.38 Million | 0.00pp |
| 2014-12-31 | 0.03% | $60.00K | $187.22 Million | -0.07pp |
| 2013-12-31 | 0.11% | $50.00K | $47.45 Million | -0.08pp |
| 2012-12-31 | 0.19% | $50.00K | $26.53 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more